Tejnaksh Healthcare Ltd (TEJNAKSH) — shareholding pattern, promoter holding, financials and share price
About Tejnaksh Healthcare Ltd (TEJNAKSH)
Tejnaksh Healthcare Ltd operates in the Healthcare Service Provider industry, within the Healthcare sector. It trades on the NSE as TEJNAKSH and on the BSE under scrip code 539428. Its ISIN is INE030T01027.
Incorporated in 2008, Tejnaksh Healthcare Ltd is in the business of Healthcare Services and Pharmacies [1]
Tejnaksh Healthcare Limited specializes in urology services, providing comprehensive healthcare solutions through its Institute of Urology in Dhule, Maharashtra.
The company transformed from a private to a public entity in 2015, expanding its service offerings and geographic presence in Maharashtra and Madhya Pradesh.
Listed peers in Healthcare Service Provider: N G Industries Ltd, Deccan Health Care Ltd, Sharma East India Hosp and Medical Research Ltd, Samsrita Labs Ltd, Chennai Meenakshi Multispeciality Hospital Ltd, Transgene Biotek Ltd.
Valuation & Returns
10 Jul 2026At ₹14.57 a share on 10 Jul 2026, Tejnaksh Healthcare Ltd (TEJNAKSH) was valued at a price-to-earnings ratio of 25.08x against an industry P/E of 61.73x and a price-to-book of 1.14x on a book value of ₹12.76 per share as of Mar 2025. Solomo computes return on equity of 4.55% and return on capital employed of 6.59% from filed results. Earnings ratios use consolidated results for the twelve months Jun 2025 to Mar 2026.
- P/E
- 25.08x
- Industry P/E
- 61.73x
- P/B
- 1.14x
- EPS (TTM)
- ₹0.58
- Book value / share
- ₹12.76
- ROE
- 4.55%
- ROCE
- 6.59%
- ROA
- 3.89%
- Debt / equity
- 0.02x
- Dividend yield
- 0%
- EBITDA margin
- 29.47%
- 52-week range
- ₹10.65 – ₹20.75
Ratios are computed from filed results and the last recorded price. Not investment advice.
Financial Performance
Mar 2026In the year ended Mar 2026, Tejnaksh Healthcare Ltd (TEJNAKSH) reported revenue of ₹10.79 crore, net profit of ₹1.18 crore and earnings per share of ₹0.61. That compares with revenue of ₹12.9 crore and net profit of ₹2.23 crore in Mar 2025. Figures are consolidated, as filed with the exchanges.
In the quarter ended Mar 2026, revenue was ₹2.55 crore and net profit ₹0.35 crore (consolidated).
| Metric | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|---|
| Revenue (₹ cr) | 12.68 | 11.73 | 12.18 | 12.9 | 10.79 |
| Net profit (₹ cr) | 2.81 | 1.79 | 1.77 | 2.23 | 1.18 |
| EPS (₹) | 1.34 | 0.83 | 0.88 | 1.15 | 0.61 |
| Measure | 10Y | 5Y | 3Y | 1Y |
|---|---|---|---|---|
| Sales growth | 7.10% | -5.21% | 2.72% | 5.91% |
| Profit growth | 7.91% | 6.39% | 1.34% | 26.70% |
| Stock price CAGR | 4% | -18% | -27% | -30% |
Ownership Summary
Jun 2026As of Jun 2026, promoters hold 73.83% of Tejnaksh Healthcare Ltd (TEJNAKSH) (unchanged from the previous quarter). Market capitalisation was ₹30 crore on 10 Jul 2026. Shareholding is filed quarterly with BSE and NSE; Solomo carries every filing back to Mar 2016.
Largest disclosed public shareholders in Jun 2026: SHEETAL UTKARSH RAWANDALE 1.45%, SONAL LOHIA 1.35%, HUF 1.02%. Only stakes above the 1% disclosure threshold are named in filings.
| Quarter | Promoter | Pledged | FII | DII | Public |
|---|---|---|---|---|---|
| Jun 2026 | 73.83% | - | - | - | 26.17% |
| Mar 2026 | 73.83% | - | - | - | 26.17% |
| Dec 2025 | 73.83% | - | - | - | 26.17% |
| Sep 2025 | 73.83% | - | - | - | 26.17% |
| Jun 2025 | 73.83% | - | - | - | 26.17% |
| Mar 2025 | 73.83% | - | - | - | 26.17% |
| Dec 2024 | 73.83% | - | - | - | 26.17% |
| Sep 2024 | 73.83% | - | - | - | 26.17% |